↓ Skip to main content

The diagnosis and management of NK/T-cell lymphomas

Overview of attention for article published in Journal of Hematology & Oncology, April 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)

Mentioned by

4 tweeters
1 Facebook page
2 Wikipedia pages


98 Dimensions

Readers on

119 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
The diagnosis and management of NK/T-cell lymphomas
Published in
Journal of Hematology & Oncology, April 2017
DOI 10.1186/s13045-017-0452-9
Pubmed ID

Eric Tse, Yok-Lam Kwong


Extranodal natural killer (NK)/T-cell lymphoma is an aggressive malignancy of putative NK-cell origin, with a minority deriving from the T-cell lineage. Pathologically, the malignancy occurs in two forms, extranodal NK/T-cell lymphoma, nasal type; and aggressive NK-cell leukaemia. Lymphoma occur most commonly (80%) in the nose and upper aerodigestive tract, less commonly (20%) in non-nasal areas (skin, gastrointestinal tract, testis, salivary gland), and rarely as disseminated disease with a leukemic phase. Genetic analysis showed mutations of genes involved in the JAK/STAT pathway, RNA assembly, epigenetic regulation, and tumor suppression. In initial clinical evaluation, positron emission tomography computed tomography, and quantification of plasma EBV DNA are mandatory as they are useful for response monitoring and prognostication. In stage I/II diseases, combined chemotherapy and radiotherapy (sequentially or concurrently) is the best approach. Conventional anthracycline-containing regimens are ineffective and should be replaced by non-anthracycline-containing regimens, preferably including L-asparaginase. Radiotherapy alone is associated with high systemic relapse rates and should be avoided. In stage III/IV diseases, non-anthracycline-regimens-containing L-asparaginase are the standard. In relapsed/refractory cases, blockade of the programmed death protein 1 has recently shown promising results with high response rates. In the era of effective non-anthracycline-containing regimens, autologous haematopoietic stem cell transplantation (HSCT) has not been shown to be beneficial. However, allogeneic HSCT may be considered for high-risk or advanced-stage patients in remission or relapsed/refractory patients responding to salvage therapy. Prognostic models taking into account presentation, interim, and end-of-treatment parameters are useful in triaging patients to different treatment strategies.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 119 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Unknown 118 99%

Demographic breakdown

Readers by professional status Count As %
Other 23 19%
Student > Postgraduate 20 17%
Researcher 16 13%
Student > Bachelor 12 10%
Student > Ph. D. Student 9 8%
Other 23 19%
Unknown 16 13%
Readers by discipline Count As %
Medicine and Dentistry 66 55%
Biochemistry, Genetics and Molecular Biology 15 13%
Agricultural and Biological Sciences 5 4%
Neuroscience 4 3%
Nursing and Health Professions 2 2%
Other 6 5%
Unknown 21 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 March 2019.
All research outputs
of 14,437,320 outputs
Outputs from Journal of Hematology & Oncology
of 701 outputs
Outputs of similar age
of 217,816 outputs
Outputs of similar age from Journal of Hematology & Oncology
of 1 outputs
Altmetric has tracked 14,437,320 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 701 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 217,816 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them